BioLineRx (NASDAQ:BLRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report report published on Tuesday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright dropped their target price on BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, November 25th.

BioLineRx Price Performance

NASDAQ BLRX opened at $0.23 on Tuesday. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.52 and a quick ratio of 1.37. BioLineRx has a 1-year low of $0.22 and a 1-year high of $1.77. The stock has a market capitalization of $17.99 million, a price-to-earnings ratio of -1.02 and a beta of 1.40. The business’s fifty day moving average price is $0.39 and its 200-day moving average price is $0.58.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. PVG Asset Management Corp bought a new stake in shares of BioLineRx during the 2nd quarter valued at $70,000. Atria Investments Inc lifted its position in BioLineRx by 27.9% during the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 29,193 shares in the last quarter. Finally, CVI Holdings LLC bought a new stake in BioLineRx during the second quarter valued at about $462,000. 1.56% of the stock is currently owned by institutional investors.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.